BIBW 1199.14 NSCLC second line
Laufzeit: 01.01.2011 - 31.12.2011
Kurzfassung
Randomized, double-blind trial of oral BIBF1120 plus standard pemetrexed therapy versus placebo plus standard pemetrexed therapy stage IIIB/IV or recurrent NSCLC in second line
